You are using an outdated browser. Please upgrade your browser to improve your experience.

You are using an outdated browser.

To ensure optimal security, this website will soon be unavailable on this browser. Please upgrade your browser to allow continued use of ACP websites.

AFib and Aflutter: Chronic Anticoagulation Therapy

Percentage of patients aged 18 years and older with a diagnosis of nonvalvular atrial fibrillation or atrial flutter whose assessment of the specified thromboembolic risk factors indicate one or more high-risk factors or more than one moderate risk factor, as determined by CHADS2 risk stratification, who are prescribed warfarin OR another oral anticoagulant drug that is FDA approved for the prevention of thromboembolism .

Date Reviewed: March 19, 2017

Measure Info

MIPS 326NQF 1525CMS 326NQF EndorsedCQMC Core Measure
Measure Type: 
Measure Steward: 
American College of Cardiology
Clinical Topic Area: 

Care Setting: 
Clinician Office/Clinic
Data Source: 

ACP supports QPP measure 326: “Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy” because implementation may lead to meaningful improvements in clinical outcomes and a performance gap exists. While we support this measure, implementation could result in underuse of appropriately prescribed anticoagulation therapy. Denominator specifications include exclusion criteria for patients with a documented reason for not prescribing therapy. Inclusion of such broad exclusion criteria may discourage clinicians from prescribing therapy in patients where the benefits outweigh the risk of harms (e.g., documentation of "fall risk"). Developers should consider explicitly defining exclusion criteria to prevent underuse of anticoagulation therapy in clinically appropriate cases. Additionally, developers cite outdated evidence to form the basis of the measure. Developers should update the denominator specifications to include the CHADs2VASc risk stratification tool.